Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Long-Term Deferred Tax (2020 - 2025)

Historic Long-Term Deferred Tax for Nutex Health (NUTX) over the last 5 years, with Q2 2025 value amounting to $12.9 million.

  • Nutex Health's Long-Term Deferred Tax changed N/A to $12.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $12.9 million, marking a year-over-year change of. This contributed to the annual value of $8.0 million for FY2024, which is N/A changed from last year.
  • As of Q2 2025, Nutex Health's Long-Term Deferred Tax stood at $12.9 million.
  • In the past 5 years, Nutex Health's Long-Term Deferred Tax ranged from a high of $12.9 million in Q2 2025 and a low of $2.4 million during Q3 2022
  • Its 4-year average for Long-Term Deferred Tax is $5.0 million, with a median of $2.4 million in 2021.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first skyrocketed by 9979.7% in 2021, then tumbled by 3852.58% in 2022.
  • Nutex Health's Long-Term Deferred Tax (Quarter) stood at $3.9 million in 2021, then tumbled by 38.53% to $2.4 million in 2022, then skyrocketed by 232.79% to $8.0 million in 2024, then soared by 60.91% to $12.9 million in 2025.
  • Its Long-Term Deferred Tax was $12.9 million in Q2 2025, compared to $10.5 million in Q1 2025 and $8.0 million in Q4 2024.